Wes Wheeler Appointed as CEO by Marken's Board of Directors
The Marken Board of Directors is pleased to announce the appointment of Wesley P. Wheeler, MBA as Chief Executive Officer. Mr. Wheeler succeeds Gerard Barba, who willremain the Chairman of the Marken Board of Directors.
Marken’s Board and executive management team have sought to add an executive such as Mr. Wheeler for his in depth of experience in the life science industry as well as a strong background in logistics to further strengthen market leadership and maintain Marken’s growth path.
Prior to joining Marken, Wes held the title of President and CEO of Patheon Inc., a contract manufacturing services company. Wes was also a former President of Valeant Pharmaceuticals International, and has previously held senior executive roles of increasing responsibility in manufacturing, marketing and engineering at GlaxoSmithKline, plc. Preceding his 22 year career in pharmaceuticals, Mr. Wheeler had a successful 12 year career at ExxonMobil. He holds a bachelor’s degree in Mechanical Engineering and aMasters of Business Administration.
“As the nature of biopharmaceutical R&D changes, well controlled clinical supply chains will be a significant factor in the success of key life science companies and the industries that support them. The Board and I feel that Wes can bring his experience from the drug manufacturing, biotechnology, and traditional pharmaceutical industries to augment an already strong management team and continue Marken’s growth”, said Gerard Barba,Marken’s Chairman.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
